Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes
Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin
A closer look at heart failure drugs: particular benefits and problems.
27 August 2021
ESC Premium Access
The practicalities of drug treatment in heart failure - Chat Moderator.
27 August 2021
ESC Premium Access
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage